Build­ing on its reti­nal dis­ease ex­per­tise, Re­gen­eron signs eye-fo­cused gene ther­a­py pact with Ger­man biotech

Re­gen­eron beefed up its gene ther­a­py ca­pa­bil­i­ties Wednes­day, sign­ing a new deal with the Ger­man biotech Vi­Gen­eron.

The sim­i­lar­ly named — but un­re­lat­ed — com­pa­nies an­nounced the col­lab­o­ra­tion ear­ly Wednes­day morn­ing, one which would see Vi­Gen­eron re­ceive undis­closed up­front and mile­stone pay­ments in ex­change for Re­gen­eron get­ting ac­cess to its suite of re­com­bi­nant ade­no-as­so­ci­at­ed virus vec­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER